Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032
Overview
The Malaysia Non-Small Cell Lung Cancer Diagnostics Market is expected to reach a 42.63 USD Million by 2032 and is projected to grow at a CAGR of 26.11% from 2025 to 2032.
Revenue, 2024 (USD Million)
12.93
Forecast, 2032 (USD Million)
42.63
CAGR, 2024 - 2032
26.11%
Report Coverage
Malaysia
Malaysia Non-Small Cell Lung Cancer Diagnostics Market 2018-2032 USD Million
Malaysia Non-Small Cell Lung Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 12.93 USD Million
- Projected Market Size (2032): 42.63 USD Million
- CAGR (2025-2032): 26.11%
Key Findings of Malaysia Non-Small Cell Lung Cancer Diagnostics Market
- The Malaysia Non-Small Cell Lung Cancer Diagnostics Market was valued at 12.93 USD Million in 2024.
- The Malaysia Non-Small Cell Lung Cancer Diagnostics Market is likely to grow at a CAGR of 26.11% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Molecular Test in Test Segment accounted for the largest share of the market with a revenue of 6.84 USD Million
- The fastest growing segment Imaging Test in Test Segment grew Fastest with a CAGR of 29.69% during the forecast period from 2024 to 2032.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Scope
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Test
- Thorecentesis
- Sputum Cytology
- Biopsy
- Others
- Immunohistochemistry
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 12.93 USD Million |
| Market Value in 2032 | 42.63 USD Million |
| CAGR (2025-2032) | 26.11% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Test,End User,Lung Cancer Type,Product |
Regional Insights:
-
Leading Market (2024-2032): Malaysia, leading in terms of revenue 12.93 USD Million in 2024
- Key Country: Malaysia, leading in terms of revenue with value of 12.93 USD Million in 2024.
Segments and Scope
-
Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Test
- Molecular Test is the largest segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 6.84 USD Million in the year 2024.
- Imaging Test is the Fastest growing segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 26.01 % in forecast period 2025-2032.
-
Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032, By End User
- Clinical Laboratories is the largest segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 4.68 USD Million in the year 2024.
- Clinical Laboratories is the Fastest growing segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 27.63 % in forecast period 2025-2032.
-
Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Lung Cancer Type
- Lung Adenocarcinoma (LUAD) is the largest segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 6.65 USD Million in the year 2024.
- Lung Adenocarcinoma (LUAD) is the Fastest growing segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 26.59 % in forecast period 2025-2032.
-
Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Product
- Reagents and Kits is the largest segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 5.74 USD Million in the year 2024.
- Reagents and Kits is the Fastest growing segment in Malaysia Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 26.90 % in forecast period 2025-2032.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| QIAGEN | |||
| Quest Diagnostics Incorporated | |||
| Abbott | |||
| General Electric | |||
| F. Hoffmann-La Roche Ltd. | |||
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Malaysia Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Test,End User,Lung Cancer Type,Product.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 12.93(Revenue in USD Million) in 2020.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 26.11% during the forecast period of 2024 to 2032.
The Molecular Test segment is expected to dominate the Malaysia Non-Small Cell Lung Cancer Diagnostics Market, holding a largest market share of 6.84 USD Million in 2024
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Scope
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Test
- Thorecentesis
- Sputum Cytology
- Biopsy
- Others
- Immunohistochemistry
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Frequently Asked Questions
The Malaysia Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Test,End User,Lung Cancer Type,Product.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 12.93(Revenue in USD Million) in 2020.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 26.11% during the forecast period of 2024 to 2032.
The estimated market value of the Malaysia Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 42.63 (USD Million).
Malaysia Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The Malaysia Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Test,End User,Lung Cancer Type,Product.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 12.93(Revenue in USD Million) in 2020.
Malaysia Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 26.11% during the forecast period of 2024 to 2032.
The estimated market value of the Malaysia Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 42.63 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.